PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Kleinovink, Jan Willem ^a   Marijt, Koen A ^a   Schoonderwoerd, Mark J A ^a   van Hall, Thorbald ^a   Ossendorp, Ferry ^a   Fransen, Marieke F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; checkpoint blockade; expression; immunotherapy; PD 1; PD L1

Indexed keywords

CHECKPOINT KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 BLOCKING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CRISPR CAS SYSTEM; FLOW CYTOMETRY; GENE INACTIVATION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; T CELL DEPLETION; TUMOR MICROENVIRONMENT;

EID: 85017144444     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1294299     Document Type: Article

References (22)

1. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 2016; 34:539–573; PMID:26927206; http://dx.doi.org/10.1146/annurev-immunol-032414-112049
2. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:Mechanisms, response biomarkers, and combinations. SciTransl Med 2016; 8:328rv4–328rv4; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
3. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J ClinOncol 2015; 33:1974–1982; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
4. Fehrenbacher, L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387:1837–1846; PMID:26970723; http://dx.doi.org/10.1016/S0140-6736(16)00587-0
5. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909–1920; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
6. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223; PMID:23243584; http://dx.doi.org/10.4161/onci.21335
7. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577–581; PMID:25428507; http://dx.doi.org/10.1038/nature13988
8. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med 2012; 4:127ra37–127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
9. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 2016; 534:402–406; PMID:27281199; http://dx.doi.org/10.1038/nature18294
10. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). ProcNatlAcadSci 2008; 105; 20852–20857; PMID:19088198; http://dx.doi.org/10.1073/pnas.0810958105
11. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84–88; PMID:17159987; http://dx.doi.org/10.1038/nm1517
12. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563–567; PMID:25428504; http://dx.doi.org/10.1038/nature14011
13. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572–576; PMID:25428506; http://dx.doi.org/10.1038/nature14001
14. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 2014; 15:190; PMID:24621249; http://dx.doi.org/10.1186/1471-2164-15-190
15. Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 2015; 3:1308–15; PMID:26546452; http://dx.doi.org/10.1158/2326-6066.CIR-15-0116
16. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances:a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27:147–153; PMID:26483045; http://dx.doi.org/10.1093/annonc/mdv489
17. Schats KA, Van Vré EA, De Schepper S, Boeckx C, Schrijvers DM, Waelput W, Fransen E, VandenBempt I, Neyns B, De Meester I, et al. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology 2017; 70:253–263; PMID:27496355; http://dx.doi.org/10.1111/his.13056
18. Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al. Tumor-Intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res 2016; 76:6964–6974; PMID:27671674; http://dx.doi.org/10.1158/0008-5472.CAN-16-0258
19. van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, van der Burg SH, van Hall T. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate Intratumoral macrophages required for tumor regression. Cancer Immunol Res 2015; 3:1042–1051; PMID:25888578; http://dx.doi.org/10.1158/2326-6066.CIR-15-0052
20. Marigo I. Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 2016; 30:377–390; PMID:27622331; http://dx.doi.org/10.1016/j.ccell.2016.08.004
21. Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res 2017; 5:106–117; PMID:28073774; http://dx.doi.org/10.1158/2326-6066.CIR-16-0391
22. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001; 2:261–268; PMID:11224527; http://dx.doi.org/10.1038/85330